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1 Introduction
Particulate guanylate cyclase [9] activity is stimu-
lated by several hormones through membrane-
receptor mediated effects and by nitrosovasodila-
tors through a direct, receptor independent mech-
anism. The end result is increased synthesis of
intracellular 3'5'-cyclic guanosine monophosphate.
The latter is thought to mediate vasodilation. The
many and diverse effects of atrial natriuretic pep-
tide (ANP) are brought about through specific
plasma membrane ANP receptors, a subtype of
which appears to be coupled to particulate guan-
ylate cyclase [7, 8]. We and others have previously
demonstrated the presence of ANP receptors in
human placentas [5, 10]. In a preliminary report,
it was shown that these receptors may be coupled
to guanylate cyclase activity [11], We have also
presented data suggesting that the affinity of ANP
placental receptors for alpha-hANP is decreased
in association with severe toxemia of pregnancy
[6]. Thus, we have asked the question whether a
decrease in the affinity of ANP placental receptors
for alpha-hANP is associated with a decrease in
ANP-dependent guanylate cyclase activity. To
complement the latter, we have also measured
receptor-independent enzymatic stimulation by a
nitrosovasodilator, sodium azide.
2 Materials and methods
2.1 Patients
They were randomly selected. Gestational ages
ranged from 27—41 weeks. Severe toxemia of
pregnancy was defined according to previously
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2.2 Materials
Nonradioactive alpha-hANP (124—151) was ob-
tained from Peninsula Laboratories. a-32P-guan-
osine triphosphate (a-32P-GTP, 25 Ci/mmol) and
3H-3'5'-cyclic guanosine monophosphate (3H-
cGMP, 16 Ci/mmol) were obtained from New
England Nuclear. The other reagents were ob-
tained commercially and were of the highest purity
available.
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2.3 Tissue
Human placentas from normal and severely tox-
emic pregnant patients were obtained at 27—41
weeks gestation immediately following delivery
and placed on ice. Fetal membranes and large
vessels were then removed by sharp dissection and
the placenta was separated into fragments, each
one weighing approximately 25 — 50 grams. These
aliquots were then frozen in liquid nitrogen and
stored at — 70 °C until needed for the assay. Under
these conditions, no significant loss in ANP-recep-
tor binding or ANP-dependent guanylate cyclase
function was noted with freezing and storage for
up to six months.
2.4 Membrane preparations [5]
On the day of the assay approximately 5 — 10
grams of each placenta were allowed to thaw in
45 — 50 ml of ice-cold, 0.9% sodium chloride
(NaCl), 20 mM Tris hydrochloride (Tris-HCl), 250
mM sucrose, 5 mM ethylenediaminetetraacetic
acid (EDTA), pH 7.5. All subsequent procedures
were carried out at 4 °C. The placenta was minced
with scissors and subsequently homogenized with
a Brinkman polytron on setting #7, twice, each
cycle lasting approximately 30 seconds with a 30
second cooling period between homogenizations.
This crude homogenate was filtered through
cheesecloth and spun at 40,000 χ g for 15 minutes.
The pellet was resuspended and recentrifuged as
before, twice. The pellet was resuspended in 0.9%
NaCl, 20 mM Tris-HCl and 5mM ethylenebis-
(oxyethylene-nitrilo)tetraacetic acid (EGTA), pH
7.5. The final concentration was approximately
4—10 mg of protein/ml.
2.5 Guanylate cyclase assay [4]
The conversion of oc-32P-GTP to 32P-cyclic-3'5'
GMP was measured in this assay. Aliquots of
placental membrane fragments (350 — 600 μg pro-
tein/tube) were incubated at 37 °C for 10 minutes
in an assay buffer that contained the following
(final concentrations): l-methyl-3-isobutyxanthine
(0.75 mM), theophylline (1 mM), creatine phos-
phate (10 mM), creatine phosphokinase (60 μg),
manganese chloride (5 mM), magnesium chloride
(5 mM), guanosine triphosphate (1 mM), 3'5'-
cyclic GMP (cGMP) (0.5 mM), and approximately
3-5 χ 106 cpm of oc-32P-GTP. The reaction was
stopped with a solution containing sodium dode-
cyl sulfate (SDS, 2.5%), cyclic GMP (1 mM), GTP
(2.5 mM), 20 mM Tris-HCl, pH 7.5. Ή-cGMP
(approximately 2,000 — 3,000 cpm per tube) was
added to each tube to monitor the recovery. The
suspension was boilded for 5 minutes. Cyclic GMP
was isolated by sequential chromatography using
Dowex (AG 50 W-X4) and alumina (WTO-neu-
tral) columns. The recovery ranged from 40 —
50%. Results have been corrected for recovery.
Basal enzymatic activity was measured in the ab-
sence of oc-hANP or sodium azide (NaN3). Stim-
ulation of guanylate cyclase activity was measured
in the presence of oc-hANP (0.5 μηι) or NaN3 (100
μιη) + catalase.
The amount of protein in the assay was deter-
mined by the method of Bradford [3] using bovine
serum albumin as the standard. Radioactivity was
counted in a scintillation counter. The results are
presented as pmol of cyclic GMP generated per
milligram of protein per 10 minutes. Statistical
analysis is carried out by the Student t test and
FISHER'S exact probability test. A p value of < 0.05
is considered as being statistically significant.
3 Results
The two groups were comparable with regards to
maternal age, gravidity, parity, mode of delivery,
and anesthesia (table I). All normal patients were
normotensive and showed no proteinuria. In con-
trast, all toxemic patients were hypertensive (BP
> 150/100) and demonstrated significant protein-
uria (> 4.5 gm/24 hours). In addition, one patient
showed thrombocytopenia and elevated liver en-
zymes. As expected, because of the severity of their
disease, toxemic patients were delivered at an ear-
lier point in gestation than the normal patients.
Although the Apgar scores were similar in the two
groups, there was one neonatal death in the tox-
emic group due to complications of prematurity.
In the antepartum period, toxemic patients had
received MgSO4 and hydralazine.
Table II shows guanylate cyclase activity in pla-
centas from normal as well as severely toxemic
patients. The results were normalized by log trans-
formation of the data. Raw data were used for
calculating the percent increase over basal activity.
There was no significant difference with regards
to basal guanylate cyclase activity between the two
groups. However, stimulation of guanylate cyclase
activity by ANP at the maximum concentration
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f Mean ± SEM, (n) = number of patients
* p < 0.005
of ANP studied (0.5 μΜ) was higher in normal
than in toxemic placentas. The percent increase of
enzymatic activity compared to basal was signifi-
cantly higher in placentas from normal patients
than from severely toxemic patients.
We next measured stimulation of guanylate cyclase
activity by a nitrovasodilator. We used sodium
azide (NaN3), with or without catalase. In some
tissues, catalase has been found to be a necessary
co-factor for NaN3-induced guanylate cyclase
stimulation [9]. Guanylate cyclase was stimulated
by NaN3 but exhibited a higher degree of activity
in the presence of catalase in both groups of pa-
tients (table III). The percent stimulation over
basal enzymatic activity was significantly higher
in placentas from normal than in those from se-
verely toxemic patients.
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f Mean + SEM; (n) = number of patients
§(%) = % increase over basal activity
* p = 0.048
** p = 0.04l
4 Discussion
In these experiments we have demonstrated that
there is an ANP-dependent guanylate cyclase ac-
tivity in placentas obtained both from normal and
severly toxemic patients. Moreover, we have
shown that although the basal activities are simi-
lar, the percent increase in ANP-dependent guan-
ylate cyclase activity is lower in toxemic placentas
than in placentas from normal women at term.
Finally, the percent increase in nitrovasodilator-
induced (NaN3) placental guanylate cyclase activ-
ity was also lower in toxemic than in normal
patients.
Guanylate cyclase is thought to be involved in
regulating vascular tone [9]. Stimulation of this
enzyme results in intra-cellular release of cyclic
GMP. The latter is thought to mediate vasodila-
tion. Several hormones, including ANP, stimulate
guanylate cyclase through binding to specific
membrane receptors. Another class of com-
pounds, the so-called nitrosovasodilators, stimu-
late this enzyme directly via a nitric oxide depend-
ent mechanism. In either case, production of
cGMP is presumed to induce phosphorylation of
similar or identical substrates that ultimately me-
diate vasodilation.
The role of cGMP in terms of placental hemody-
namics has not been adequately investigated. Basal
guanylate cyclase activity may not necessarily re-
flect the functional properties of the tissue. Thus,
we chose to examine this enzymatic activity in a
more dynamic fashion, i.e. stimulated activity.
Our observation that the stimulated cyclase activ-
ity is reduced in placentas from toxemic patients
suggests that there might be an association be-
tween certain aspects of placental hemodynamic
regulation and guanylate cyclase activity. While
ANP appears to be an important factor in terms
of guanylate cyclase stimulation in placental
plasma membranes, it is by no means the only
factor that may influence its overall function. This
is supported by our results concerning NaN3-de-
pendent enzymatic activity. However, in placentas
for severely toxemic patients, the percent stimu-
lation of guanylate cyclase activity is decreased
both in the case of ANP as well as in the case of
a nitrosovasodilator, NaN3.
ANP effects are mediated through specific plasma
ANP receptors. One subtype of these receptors is
coupled to guanylate cyclase [7, 8]. A second sub-
type of ANP receptor has been shown to mediate
its effects independent of guanylate cyclase [7].
However, in the latter case, the nature of the
second messenger is not known. Although guan-
ylate caclase is found both in the plasma mem-
brane as well as in cytoplasmic fractions, as these
experiments suggest and as we have previously
discussed, placental ANP receptors are presumed
to be located in a microsomal plasma membrane
fraction which is thought to be exposed primarily
to fetal blood [5].
While these observations support our previously
reported results on placental ANP binding char-
acteristics [6], they cannot answer the question
whether they represent a primary or secondary
event in patients with toxemia of pregnancy. Other
confounding variables, such as gestational age,
maternal treatment with MgSO4 or antihyperten-
sive agents, might have influenced the results. Fi-
nally, there are conflicting reports [2, 12, 13] with
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regards to maternal plasma ANP concentrations
in toxemia of pregnancy. Whereas some investi-
gators have reported them to be higher than in
normals [2, 13], others have not been able to
confirm those results [2]. It is not known whether
fetal ANP levels are altered in toxemia of preg-
nancy. Further experiments need to be designed
to answer these specific questions.
Abstract
Participate guanylate cyclase is stimulated by several
hormones through receptor-dependent and by nitroso-
vasodilators through receptor-independent mechanisms.
A subtype of atrial natriuretic peptide (ANP) receptors
is coupled to guanylate cyclase. It has been shown that
there is a down-regulation of the affinity of ANP recep-
tors to -hANP in placental plasma membranes obtained
from severely toxemic patients. We have asked the ques-
tion whether these changes are associated with a down-
regulation of ANP-dependent guanylate cyclase activity.
Guanylate cyclase was determined by in vitro experi-
ments using a placental plasma membrane fraction ob-
tained from normal and from severely toxemic patients.
The presence of ANP-dependent placental guanylate
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cyclase activity was demonstrated both in normal and
toxemic placentas. Although basal guanylate cyclase ac-
tivity was not influenced by toxemia of pregnancy, there
was a significant decrease in the maximum stimulation
of this enzyme by a-hANP (104.81 ± 12.02% (n = 4)
vs 49.41 ± 8.73% (n = 7) for normal and toxemics,
respectively). Finally, stimulation by a nitrosovasodila-
tor, sodium azide (NaN3), was also lower in toxemic
placentas than in normal controls. These observations
extend our previously reported results on placental ANP
receptor function but also suggest the presence of a
possibly receptor-independent decrease in guanylate cy-
clase activity in toxemic placentas.
Zusammenfassung
Atriale natriuretische Paptide und die Aktivität von NaN3-
abhängigen Guanylatcyclasen in Plazenten von gesunden
und schwer toxikotischen Patientinnen
Speziell die Guanylatcyclase wird rezeptorabhängig
durch verschiedene Hormone und rezeptorunabhängig
durch Nitroso-Vasodilatatoren stimuliert. Das atriale
natriuretische Peptid (ANP) ist ein Hormon, dessen Se-
kretion durch Muskelzellen im Vorhof über einen an-
steigenden intraartrialen Druck und über eine Zunahme
der Vorhofdehnung gesteuert wird. Die Wirkungen des
ANP werden über spezifische Plasmamembranrezepto-
ren vermittelt. Ein Subtyp der ANP-Rezeptoren ist an
die Guanylatcyclase gekoppelt. Es konnte gezeigt wer-
den, daß in plazentaren Plasmamembranen von schwer
toxikotischen Patientinnen die Affinität der ANP-Re-
zeptoren für -hANP abnimmt. Unsere Fragestellung
war, ob diese Veränderungen mit einer Verminderung
der ANP-abhängigen Guanylatcyclase-Aktivität assozi-
iert sind. Durch in vitro-Experimente erhielten wir Gua-
nylatcyclase aus plazentaren Plasmamembranfraktionen
von gesunden und schwer toxikotischen Patientinnen.
Die Konversion von oc-32-P-GTP zu cyclischem 32P-GMP
wurde basal sowie nach Stimulation gemessen. Das cyc-
lische GMP wurde durch Sequenzchromatografie isoliert
und dann quantifiziert. Es erfolgten Korrekturen für die
prozentuale Wiederfindungsrate und den Proteingehalt.
Sowohl in normalen wie in toxikotischen Plazenten war
eine ANP-abhängige Guanylatcyclase-Aktivität nach-
weisbar. Obwohl die basale Guanylatcyclase-Aktivität
(ausgedrückt als log-pmol/mg Protein/min) nicht durch
eine Toxikose in der Schwangerschaft beeinflußt war
(normal: 2.231 ±0.703, n = 4; toxikotische: 1.955
Schlüsselwörter: ANP, Guanylatcyclase-Aktivität, NaN3, Plazenta beim Menschen, Schwangerschaftstoxikose.
±0.196, n = 7) zeigte sich ein signifikanter Abfall in
der prozentualen Stimulation dieses Enzyms durch a-
hANP (normal: 104.81 ± 12.02%, toxikotisch: 49.41
± 8.73%). Schließlich war die prozentuale Stimulation
durch einen Vasodilatator, NaN3, in toxikotischen Pla-
zenten auch geringer als bei den Kontrollen (102.11
± 28.04% vs. 198.95 ± 19.86%). Man nimmt an, daß
die Guanylatcyclase bei der Regulation des vaskulären
Tonus beteiligt ist. Eine Stimulation dieses Enzyms be-
wirkt eine intrazelluläre Freigabe von cyclischem GMP,
das die Vasodilatation induzieren kann. Die Funktion
des cGMP bei der plazentaren Hämodynamik wurde
bisher noch nicht ausreichend untersucht. Unsere Be-
obachtungen weisen darauf hin, daß ein möglicher Zu-
sammenhang zwischen der hämodynamischen Regula-
tion der Plazenta und der Guanylatcyclase-Aktivität be-
steht. Wenn auch das ANP ein wichtiger Faktor bei der
Guanylatcyclase-Stimulation in Plazentamembranen ist,
so handelt es sich keinesfalls um den einzigen Faktor
bei der Beeinflussung der Gesamtfunktion. Dies zeigen
auch unsere Ergebnisse mit der NaN3-abhängigen En-
zymaktivität. Auf jeden Fall ist die Enzymstimulation
sowohl beim ANP wie auch beim Nitroso-Vasodilatator
NaN3 gesenkt. Diese Beobachtungen unterstützen unsere
bereits veröffentlichten Ergebnisse hinsichtlich der Ab-
nahme der Affinität des plazentaren ANP-Rezeptors für
-hANP bei Toxikosen. Wir können jedoch nicht die
Frage beantworten, ob damit bei Patientinnen mit
Schwangerschaftstoxikosen eine Ursache oder ein Fol-
gezustand beschrieben wird. Weitere Untersuchungen
sind notwendig, um diese spezifischen Fragen zu klären.
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Resume
Peptide atrial natriuretique et activite guanylate cyclase
sodium azide dependante au niveau de placentas provenant
de patientes normales et avec toxemie severe
La guanylatecyclase est stimulee par plusieurs hormones
selon des mecanismes recepteurs dependants et par des
nitrosovasodilateurs selon des mecanismes non recep-
teurs dependants. Le peptide atrial natriuretique (ANP)
est une hormone dont la secretion par les intra-atriale
et de la tension atriale. Les effets induits par FANP
s'exercent par Pintermediare de recepteurs membranaires
specifiques. Un sous type de recepteur ANP est couple
la guanylate cyclase. II a ete montre qu'il existe une
diminution de Faffinite des recepteurs ANP pour l'oc-h
ANP dans les membranes du plasma placentaire en
provenance de patientes atteintes de toxemie severe.
Nous nous sommes demandes si ces modifications
s'accompagnent d'un freinage de l'activite guanylate cy-
clase ANP dependante. La guanylate cyclase a ete etu-
diee par des experiences in vitro en utilisant des fractions
de membrane du plasma placentaire provenant de pa-
tientes normales et atteintes de toxemie severe. On a
mesure la conversion de Γα32 P.GTP en 32 P.GMP
cyclique Fetat basal et apres stimulation. Le GMP
cyclique a ete isole par Chromatographie sequentielle. Le
receuil ete surveille. Les resultats ont ete corriges en
pourcent de receuil et en quantite de proteine. On a
demontre la presence d'activite guanylate cyclase pla-
centaire AND. dependante dans les placentas normaux
et dans les placentas de toxemiques. Bien que l'activite
guanylate cyclase de base exprimee en log (pmol/mg de
proteine/min) ne soit pas influencee par la toxemie gra-
vidique (normal = 2,231 ± 0,703 (n = 4); toxemie:
1,955 + 0,196; n = 7) il y a une diminution significative
de la stimulation de cette enzyme par 1'a-hANE (104,81
± 12,02 versus 49,41 ± 8,73% respectivement pour la
normale et la toxemie). La stimulation par un nitroso-
vasodilatateur, le sodium azide, est egalement plus faible
dans les placentas de toxemiques que dans les placentas
temoins normaux (102,11 ± 28,04% VS 198,95
± 19,86%). On pense que la guanylate cyclase est im-
pliquee dans la regulation du tonus vasculaire. La sti-
mulation de cette enzyme entraine une liberation intra-
cellulaire de GMP cyclique qui peut induire une vaso-
dilatation. Le role du CGMP en terme d'hemodyna-
mique placentaire n'a pas ete explore de fagon adequate.
Les observations que nous presentons suggerent qu'il
pourrait y avoir une relation entre certains aspects de la
regulation de rhemodynamique placentaire et l'activite
guanylate cyclase. Bien que ΓΑΝΡ semble etre un facteur
important en ce qui concerne la stimulation de la gya-
nylate cyclase dans les membranes du plasma placen-
taire, ce n'est surement pas 1'unique facteur qui peut
influencer s fonction globale. Nos resultats concernant
l'activite enzymatique sodium azide dependante renforce
cette opinion. Neanmoins, la stimulation de l'enzyme
diminue avec ΓΑΝΡ aussi bien qu'avec le sodium azide,
nitrosovasodilatateur. Ces observations renforcent la di-
minution de Faffinite pour Fa-hANP des recepteurs
ANP placentaires chez les toxemiques que nous avions
anterieurement rapportee. Toutefois, les observations ne
permettent pas de repondre a la question de savoir si
cette diminution est primitive ou secondaire chez les
patientes ayant une toxemie gravidique. D'autres expe-
riences sont necessaires pour repondre ces questions
specifiques.
Mots-cles: Activite guanylate cyclase, ANP, NaN3, placenta humain, toxemie gravidique.
Comment: This work was partially presented at the 35th Annual Meeting of the Society for Gynecologic Inves-
tigation in Baltimore, Maryland, 1988.
References
[1] ACOG Technical Bulletin. Management of pree- [4]
clampsia. No. 91 (1986)
[2] BOND A, P TAUFIELD, M DRUZIN, S ATLAS, J
SEALEY, J LARAGH: Atrial natriuretic factor and
renin levels in normal and hypertensive pregnancy.
Abstract # 294 presented at the 35th Annual Meet- [5]
ing of the Society for Gynecologic Investigation,
March, 1988
(3] BRADFORD MM: A rapid and sensitive method for [6]
the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal
Biochem 72 (1976) 248
FIELD M, LH GRAF JR, WJ LAIRD, PL SMITH: Heat-
stable entero-toxin of Escherichia coli: in vitro ef-
fects on guanylate cyclase activity, cyclic GMP con-
centration, and ion transport in small intestine. Proc
Natl Acad Sei 75 (1978) 2800
HATJIS CG, DM GROGAN: Atrial natriuretic peptide
receptors (ANP) in normal human placentas. Am
J Obstet Gynecol. 159 (1988) 587
HATJIS CG, DM GROGAN: Atrial natriuretic peptide
(ANP) receptors in human placentas from normal
and severely toxemie patients. Abstract #295 pre-
sented at the 35th Annual Meeting of the Society
for Gynecologic Investigation, March, 1988
J. Perinat. Med. 17 (1989)
Hatjis & Bottoms, ANP, Guanylate cyclase activity, human placenta, NaN3, toxemia 31
[7] JACOBS JW, GP VLASUK, M ROSENBLATT: Atrial [12] SENYEI A, B KOPEREK, M PANDIAN, M PORTO: Atrial
natriuretic factor receptors. Endocrinol Metab natriuretic factor in PIH: a potential biochemical
Clinics North America 16 (1987) 63 roll over test. Abstract #255 presented at the
[8] LEITMAN DC, F MURAD: Atrial natriuretic factor Eighth Annual Meeting of the Society of Perinatal
receptor heterogeneity and stimulation of particu- Obstetricians, February, 1988
late guanylate cyclase and cyclic GMP accumula- [13] THOMSEN JK, TL STORM, G THAMSBORG, M DE
tion. Endocrinol Metab Clinics North America 16 NULLY, B BOOKER, S SKOUBY: Atrial natriuretic
(1987) 79 peptide concentrations in pre-eclampsia. Br Med J
[9] RAPAPORT RM, F MURAD: Endothelium-dependent 294 (1987) 1508
and nitrovaso-dilator-induced relaxation of vascu-
lar smooth muscle: role of cyclic GMP. J Cyclic Received September 20,1988. Accepted October 20,
Nucleotide Protein Phosphorylation Res 9 (1983) 1988.
281
[10] SEN I: Identification and solubilization of atrial Christos G. Hatjis, M.D.
natriuretic factor receptors in human placenta. Director of Perinatology
Biochem Biophys Res Comm 135 (1986) 480 Riverside Methodist Hospitals
[11] SEN I, P ROY: Atrial natriuretic factor induced phos- 3535 Olentangy River Road
phorylation of human placental membrane protein: Columbus, Ohio 43214
an effect mimicked by guanosine 3': 5'-cyclic mon- U.S.A.
ophosphate. Biochem Biophys Res Comm 139
(1986) 431
J. Perinat. Med. 17 (1989)
